Scientists Report First use of CRISPR to Substitute Genes to Treat Patients with Cancer
November 23, 2022 |
For the first time, scientists have used CRISPR gene editing technology to substitute a gene to treat patients with cancer. The new approach first identifies T cells that specifically recognize and kill an individual patient's tumor cells.
T cells are a type of immune cell, and the cells in question kill tumor cells when they encounter specific genetic mutations from cancer. However, there are often not enough of these cells. By CRISPR editing other T cells from the patient with the same cancer recognition motifs, the approach is designed to build a large army of cancer-fighting cells, which are then infused back into the patient, thus greatly amplifying that natural anti-tumor response.
The therapy approach was developed by PACT Pharma, based upon the work pioneered by Dr. Jim Heath, president of the Institute for Systems Biology (ISB), and his collaborators, UCLA Professor Dr. Toni Ribas and Caltech Professor Dr. David Baltimore. The therapy was used to treat 16 patients. The early-stage clinical trials were meant to show that the treatment was safe for patients, but the researchers also found that the engineered T cells did, in fact, home in on the patient tumors.
“This is a leap forward in developing a personalized treatment for cancer,” Ribas said. “The generation of a personalized cell treatment for cancer would not have been feasible without the newly developed ability to use the CRISPR technique to replace the immune receptors in clinical-grade cell preparations in a single step,” he added.
To learn more about this research, read the article on the ISB website, or watch this YouTube video.
|
You might also like:
- Plant Growth Study Sheds Light on Cancer Research
- Study Shows Link between CRISPR and Mutated Cancer Cells
- UK Scientists Develop Genome-edited Wheat to Reduce Cancer Risk from Bread
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
-
See more articles:
-
Gene Editing Supplement (November 23, 2022)
-
Research and Tools
- Targeted Modification of Rice Genome with Base Editing
- Tomatoes Can Now Come in Customized Colors Thanks to CRISPR
- Scientists Use Virus for Bacterial Base Editing
- Study Finds CRISPR-Cas9 Leads to Unexpected Genomic Changes
- Scientists Report First use of CRISPR to Substitute Genes to Treat Patients with Cancer
-
Public Acceptance and Engagement
- Large Chinese Seed Companies Likely to Produce Gene-Edited Crops for Farmers - Study
-
Read the latest: - Biotech Updates (November 6, 2024)
- Gene Editing Supplement (October 30, 2024)
- Gene Drive Supplement (February 22, 2023)
-
Subscribe to BU: - Share
- Tweet